1,853 material Form 8-K filings that 1,500 companies we cover made with the SEC in September 2026, each read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). All of them were written later, when past filings were added: a selection, not every 8-K of the month (see the note below).
FatPipe appointed Kanishka Ragula, age 25, as Chief Financial Officer and Principal Accounting Officer effective September 11, 2026, replacing Eric Sherb, who ceased serving in those roles on the same date. The filing says Sherb's departure was not the result of any disagreement with the company and that he will consult for FatPipe during the transition. Ragula's family relationship to the CEO and Chairman is disclosed, which shareholders may weigh when assessing the appointment.
Eric Sherb ceased serving as CFO and Principal Accounting Officer effective September 11, 2026, and will continue as a consultant.
Kanishka Ragula, age 25, was appointed CFO and Principal Accounting Officer effective September 11, 2026; he had been Director of Finance since September 2025.
Ragula will receive an annual base salary of $175,000 plus an equity grant to be approved by the board at the annual meeting.
Ragula is the son of CEO and Chairman Ragula Bhaskar, Ph.D., and of President, CTO and director Sanchaita Datta.
On September 14, 2026, Hyperliquid Strategies Inc and Chardan Capital Markets LLC signed Amendment No. 3 to their ChEF Purchase Agreement, replacing the definition of VWAP Purchase Price. After the first 160,000,000 shares are sold under the agreement, the company's VWAP-based and Intraday VWAP sales are priced at 98.5% of VWAP, and Off-Hour VWAP sales at 97.0% of VWAP. The filing does not state the number of shares expected to be sold, so its effect on existing shareholders cannot be measured from this document.
Amendment No. 3 dated September 14, 2026, amends the ChEF Purchase Agreement dated October 22, 2025, with Chardan Capital Markets LLC.
After the first 160,000,000 shares are sold, VWAP and Intraday VWAP purchases are priced at 98.5% of the VWAP over the applicable period.
Off-Hour VWAP purchases are priced at 97.0% of the VWAP; the amendment supersedes Amendment No. 2 dated September 14, 2026.
Impact Biomedical Inc. (NYSE American: IBO) said its 1-for-12.62 reverse stock split will take effect at 12:01 a.m. Eastern Time on September 23, 2026, reducing outstanding common shares from about 107.8 million to about 8.5 million. The company said the split is connected to its proposed merger with Zoar Limited and to regaining compliance with NYSE American listing requirements, but it gave no assurance that either goal will be met. The filing also corrects an earlier press release that misstated the merger exchange ratio.
Reverse split ratio of 1-for-12.62 takes effect 12:01 a.m. Eastern Time on September 23, 2026; ticker remains IBO under a new CUSIP.
Shares outstanding expected to fall from 107,821,231 to 8,543,679, subject to rounding; fractional shares are rounded up to the next whole share.
Merger terms: one Zoar Limited share for each Impact share held immediately before the merger, after giving effect to the split.
A corrected press release replaces the September 11, 2026 release, which incorrectly stated a one-for-four exchange ratio.
On September 14, 2026, Tyra Biosciences agreed to sell 9,079,000 shares of common stock and pre-funded warrants for 9,078,529 shares, with gross proceeds expected to be approximately $400.0 million before underwriting discounts and offering expenses. The offering is expected to close on September 15, 2026, and the company plans to use the net proceeds, together with existing cash, to advance its dabogratinib 3x3 development strategy, support preclinical and discovery programs, and fund working capital and general corporate purposes. Issuing these shares and warrants will dilute existing shareholders.
Offering of 9,079,000 common shares at $22.03 per share, plus pre-funded warrants for 9,078,529 shares at $22.029 per warrant
Underwriters agreed to buy the shares at $20.7082 per share; gross proceeds expected to be approximately $400.0 million
Closing expected September 15, 2026; proceeds targeted at dabogratinib 3x3 in LG-UTUC, IR NMIBC and achondroplasia
On September 14, 2026, The Trade Desk's board approved a performance-based stock option for CEO Jeff Green, who recused himself from the vote. The option allows him to buy up to 7,000,000 Class A shares at $14.97, the closing price on the grant date, but shares vest only if the stock reaches price targets from $18.00 to $105.00.
Up to 7,000,000 Class A shares under the option, with an exercise price of $14.97 per share
Seven vesting tranches with price targets from $18.00 to $105.00 per share, over a ten-year term
Vesting requires the average closing price to meet a target over any 20-consecutive-trading-day period, plus continued service
The award agreement will be filed with the Form 10-Q for the quarter ending September 30, 2026
BOXABL concluded the employment of CFO Martin Costas effective September 11, 2026, and appointed Larry King as CFO effective September 14, 2026. The company also said Heather Clayton will become Chief Accounting Officer beginning September 28, 2026. The filing says Costas's departure was not due to any disagreement with the company on operations, policies, or practices.
Martin Costas's employment as CFO concluded effective September 11, 2026; the filing states no disagreement with the company was the reason.
Larry King, 65, a Certified Public Accountant, was appointed CFO and principal financial and accounting officer effective September 14, 2026, with an annual salary of $300,000.
Heather Clayton will begin as Chief Accounting Officer on September 28, 2026, with an annual salary of $250,000.
Offer letters for King and Clayton are filed as Exhibits 10.1 and 10.2.
Calumet, Inc. entered into an amendment to its credit agreement on September 11, 2026, increasing lender commitments from $500.0 million to $600.0 million, subject to borrowing base limitations. A related amendment to its Monetization Master Agreement with J. Aron & Company LLC was made to permit the larger credit facility. The filing does not state the reasons for the change or any effect on earnings, and shareholders can expect more borrowing capacity under the facility.
Credit agreement commitments rise from $500.0 million to $600.0 million, subject to borrowing base limitations
Eleventh Amendment to the Third Amended and Restated Credit Agreement dated September 11, 2026, with Bank of America, N.A. as administrative agent
Fourth Amendment to the Monetization Master Agreement with J. Aron & Company LLC, dated September 11, 2026, permits the increase
Filed under Items 1.01, 2.03 and 9.01; signed by David Lunin, Executive Vice President and Chief Financial Officer, on September 14, 2026
Capital One furnished its monthly charge-off and delinquency metrics for the month ended August 31, 2026, in Exhibit 99.1 of this Form 8-K. The filing covers domestic credit card and auto loan credit performance, which shareholders may track as indicators of loan losses, though the release gives no prior-period comparison.
Domestic credit card net charge-offs were $892 million for August 2026, a 4.16% annualized net charge-off rate on average loans of $257,499 million.
Domestic credit card 30+ day performing delinquencies were $9,297 million, or 3.57% of period-end loans.
Auto loan net charge-offs were $126 million (1.66% rate), 30+ day performing delinquencies were $4,171 million (4.54%), and nonperforming loans were $572 million (0.62%).
Rekor Systems reconvened its 2026 Annual Meeting of Stockholders on September 11, 2026, but no business was conducted because a quorum was not present. The meeting was adjourned to October 16, 2026, with no change to the matters up for vote, and previously submitted proxies will be voted unless revoked.
Annual Meeting reconvened September 11, 2026; no business conducted due to lack of quorum
Reconvened Meeting set for October 16, 2026 at 10:30 a.m. Eastern Time, in person in Columbia, Maryland and by live webcast
Record date remains the close of business on March 25, 2026; existing proxies will be voted unless revoked
Eagle Point Credit Company disclosed in an 8-K filed September 14, 2026, that management's unaudited estimate of its net asset value per common share as of August 31, 2026 was between $4.29 and $4.39. The filing gives only the range and no prior-period comparison, so it does not show whether NAV rose or fell from the prior month.
Unaudited estimated NAV per common share range: $4.29 to $4.39
Estimate is as of August 31, 2026
Filed under Item 8.01 (Other Events) on September 14, 2026; signed by CFO and COO Kenneth P. Onorio
Eagle Point Income Company disclosed in a Form 8-K that management's unaudited estimate of net asset value per common share as of August 31, 2026, was between $12.38 and $12.48. The filing does not give a prior-period comparison, so it does not show whether the estimated range is higher or lower than before.
Estimated NAV per common share range: $12.38 to $12.48
Valuation date: August 31, 2026
Figures are management's unaudited estimate, filed September 14, 2026 under Item 8.01 (Other Events)
Chipotle Mexican Grill increased its board to 11 directors and elected Sabir Sami, a former KFC Division CEO at Yum! Brands, as an independent director effective September 14, 2026. Sami will not serve on any board committee, and his pay will follow the standard non-employee director program.
Board expanded from 10 to 11 directors; the company says 10 of 11 directors are independent
Sabir Sami, age 59, served as CEO of KFC Division at Yum! Brands from January 2022 to February 2025
Sami was not appointed to any board committee; compensation follows the non-employee director program
Toppoint Holdings said it expects to change its state of incorporation from Nevada to Delaware, with the change effective on or about September 25, 2026, after stockholder approval at the September 8, 2026 annual meeting. The filing says the company's operations, management, assets, liabilities, and listing on NYSE American under TOPP are not expected to change, and shareholders' shares will convert one-for-one.
Stockholders approved the reincorporation at the 2026 Annual Meeting held September 8, 2026; the board approved the plan on July 27, 2026.
Expected effective time is on or about September 25, 2026, subject to state filings and other customary conditions.
Authorized common shares expected to rise from 300,000,000 to 1,000,000,000 at the effective time; the increase alone does not issue new shares.
Company expects no change to operations, management, headquarters, or employees, other than costs incident to the reincorporation.
Addus HomeCare's subsidiary agreed on September 12, 2026 to acquire the personal care business of AccentCare outside New York for $275 million in cash, subject to adjustments. The company expects the deal to add about $280 million in annualized revenue, which it says would be roughly a 19% increase to its revenue base, and plans to fund it through its revolver and cash on hand. Closing depends on regulatory approvals and the Hart-Scott-Rodino waiting period, so shareholders will not see the deal's effect until it closes.
Purchase price is $275 million in cash, subject to working capital and other customary adjustments.
Company expects about $280 million in annualized personal care revenue, which its CEO describes as roughly a 19% increase to revenue.
Acquired operations serve an average daily census of about 13,700 customers across a 10-state footprint.
Closing requires regulatory approvals and the expiration of the HSR waiting period; the deal has no financing condition and no termination or reverse termination fee.
NextEra Energy and Dominion Energy issued a joint press release on September 14, 2026, announcing an enhanced Virginia benefits package under their pending Merger Agreement. The package proposes doubling $10 per month residential bill credits from two years to four years, a $100 million increase to the EnergyShare low-income assistance program, and new jobs and a Richmond office tower. The companies say these commitments depend on approval and closing of the combination, which they expect in the second half of 2027, so the filing does not change the financial results of either company.
Residential bill credits of $10 per month would run four years instead of two.
EnergyShare low-income assistance would increase by $100 million through 2038.
NextEra plans 600 new jobs in Virginia and a $100 million workforce development fund; the companies expect the transaction to close in the second half of 2027.
Z Squared completed its acquisition of Paradox Data, LLC on September 8, 2026, which holds the Union County Campus in El Dorado, Arkansas, with about 8.0 MW of existing interruptible grid power. The company paid with 5,000 shares of newly designated Series A Convertible Preferred Stock, with a stated value of $5,000,000, and issued no cash or debt for the closing. Shareholders should note the preferred stock's potential dilution, a related person transaction involving the Chief Technology Officer, and that Entergy's consent to transfer the power agreement has not been obtained.
Closing date September 8, 2026; consideration was 5,000 Series A Preferred shares with a $5,000,000 stated value, convertible at $7.45 per common share
Up to $20,000,000 more in preferred stock is payable on development milestones, none achieved; total potential consideration up to $25,000,000
Chief Technology Officer Jeffery Harris holds an indirect minority interest in the seller and in Paradox Energy LLC; the Audit Committee and Board approved the deal
Entergy Arkansas consent to assign the electric service agreement has not been obtained; the 150 MW target is not contracted or energized
On September 14, 2026, Amazon closed the sale of four series of notes with a total public offering price of £4.242 billion and estimated net proceeds of about £4.235 billion before offering expenses. The notes carry coupons from 5.200% to 6.650% and mature between 2029 and 2045, so the filing shows new long-term debt that Amazon will need to repay and service.
Four series: 5.200% notes due 2029 (£1.25 billion), 5.550% due 2032 (£1 billion), 6.250% due 2038 (£1 billion), 6.650% due 2045 (£1 billion)
Aggregate public offering price of £4.242 billion; estimated net proceeds of about £4.235 billion before offering expenses
Sold under an Underwriting Agreement dated September 9, 2026, and registered on a Form S-3 filed February 6, 2026
Equity Bancshares' board declared a quarterly cash dividend of $0.22 per common share on September 10, 2026. The dividend is payable October 15, 2026, to stockholders of record at the close of business on September 30, 2026. The routine declaration sets the cash payout shareholders on the record date will receive.
Quarterly cash dividend of $0.22 per share of common stock
Declared by the board of directors on September 10, 2026
Payable October 15, 2026, to holders of record as of September 30, 2026
Apogee Enterprises, Inc. elected Julie K. Streich as an independent director effective September 11, 2026, and appointed her to the Audit Committee; the board grew from eight to nine members. Director Patricia K. Wagner informed the board she intends to retire effective October 2, 2026, and the filing says her retirement is not due to a disagreement with the company. The filing reports no financial results, so the changes affect board composition rather than current financial performance.
Julie K. Streich, age 55, elected Class I director on September 11, 2026, with a term expiring at the 2029 Annual Meeting of Shareholders.
Streich appointed to the Audit Committee effective September 11, 2026; the board determined she is independent under Nasdaq listing standards.
Patricia K. Wagner informed the board on September 10, 2026 that she intends to retire effective October 2, 2026.
Streich receives a pro-rated fiscal 2027 cash retainer of $75,000 and a restricted stock award of 2,530 shares vesting over three years; APOG closed at $37.88 on September 11, 2026.
Bowhead Specialty Holdings elected Derek Walker, a Managing Director at Gallatin Point Capital, to its board of directors effective September 12, 2026, to fill an existing vacancy. He was recommended by GPC Partners Investments (SPV III) LP under a 2024 board nominee agreement, and he receives no board compensation because he is employed by Gallatin Point.
Walker elected to the board effective September 12, 2026, to fill a vacancy
Recommended by GPC Partners Investments (SPV III) LP under a Board Nominee Agreement dated May 23, 2024
Walker is a class II director, with his term expiring at the 2032 annual meeting; he stands for reelection at the 2029 meeting
Not eligible for cash fees or other compensation for board service because he is employed by Gallatin Point
Lument Finance Trust completed its previously announced 1-for-10 reverse stock split after the close of business on September 9, 2026, reducing outstanding common shares from 52,564,062 to approximately 5,256,400. The company said the split did not change any stockholder's percentage ownership or voting power, except for de minimis changes from cash payments for fractional shares.
Every ten outstanding common shares converted into one share; outstanding shares fell from 52,564,062 to approximately 5,256,400.
Fractional shares are paid in cash at $6.959 per share fraction.
Common stock continues to trade on the NYSE as LFT; post-split trading under new CUSIP 55025L306 starts September 10, 2026.
Stockholders were not required to take action; the transfer agent, Equiniti Trust Company, LLC, will send ownership information.
Caris Life Sciences said that starting September 14, 2026, its representatives will use an investor presentation in meetings with current and potential investors at the Morgan Stanley 24th Annual Global Healthcare Conference and at other investor events. The company will post the presentation on its investor relations website. The filing contains no financial results, guidance, or new business developments, so it offers no direct read on company performance.
Presentation to be used starting September 14, 2026 at the Morgan Stanley 24th Annual Global Healthcare Conference
Company will post the Investor Presentation at investor.carislifesciences.com
Information is furnished under Item 7.01 and is not deemed filed under Section 18 of the Exchange Act
AIM ImmunoTech Inc. exchanged approximately $400,000 of a November 18, 2025 promissory note held by Streeterville Capital, LLC into 1,749,434 shares of common stock at an average conversion price of about $0.228 per share. The transactions were carried out through two exchange agreements signed September 8 to September 9, 2026, and the shares were issued under a Securities Act exemption for exchanges with an existing holder. Because the new shares add to the outstanding share count, existing shareholders' ownership percentages are diluted, although the filing does not state the total share count.
Debt converted: approximately $400,000 of the Promissory Note dated November 18, 2025
Shares issued: 1,749,434 shares of common stock at an average conversion price of about $0.228 per share
Agreements dated September 8 to September 9, 2026, with Streeterville Capital, LLC; stockholders approved the conversion at a July 15, 2026 special meeting
Shares issued under Section 3(a)(9) of the Securities Act, with no commission paid for the exchange
TriNet's Board of Directors declared a quarterly dividend of $0.29 per share on September 11, 2026, as disclosed in a press release filed with the SEC on September 14, 2026. The record and ex-dividend date is October 1, 2026, and the dividend is payable October 26, 2026, so shareholders who hold the stock on that record date will receive the payment.
DexCom named Jereme Sylvain, its executive vice president and chief financial officer, to also serve as chief operating officer, effective September 14, 2026, with oversight of global operations and quality teams. His new offer letter sets a base salary of $767,000 and a target bonus of 75% of base salary.
Sylvain keeps his CFO role and adds the COO title, effective September 14, 2026
Base salary of $767,000; annual target bonus equal to 75% of base salary
Offer letter dated September 11, 2026; a copy will be filed with the 10-Q for the quarter ended September 30, 2026
CEO Jake Leach said Sylvain will help the company scale more effectively
On September 8, 2026, Drugs Made In America Acquisition Corp. and Power Analytics Global Corp entered an Amended and Restated Definitive Merger Agreement that replaces the existing agreement in its entirety. The parties set a fixed closing valuation of $2.85 billion for Power Analytics, replacing the prior $1.0 billion target and $300 million floor. Completion depends on conditions including shareholder approval, an acquisition of APQC Inc, and a minimum cash condition, so the deal has not closed.
Amended and Restated Definitive Merger Agreement dated September 8, 2026, replacing the Existing Agreement from April 29, 2026.
Closing valuation of $2.85 billion, replacing the $1.0 billion target valuation and $300 million floor valuation.
Merger Consideration capped at 265,116,279 Domesticated DMAA Common Shares, based on a Reference Price of at least $10.75.
Closing requires shareholder approval, completion of the APQC Acquisition and Available Closing Cash of at least $15 million.
Ramaco Resources announced the share ratio for its previously declared third-quarter 2026 Class B stock dividend, which will be paid in Class B shares rather than cash. Holders of record on September 11, 2026 will receive 0.025626 of a Class B share for each share held, based on a $5.99 closing price that day. The filing confirms terms already announced and does not report new financial results.
Declared quarterly Class B dividend of $0.1535 per share, payable in Class B shares on September 25, 2026
Ratio of 0.025626 Class B share per share held, set by dividing $0.1535 by the $5.99 Class B closing price on September 11, 2026
Fractional shares will be paid in cash based on the Class B closing price on the Record Date
Westwater Resources Executive Chairman Terence Cryan presented at the H.C. Wainwright 28th Annual Global Investment Conference on September 14, 2026, and the company furnished the investor presentation as Exhibit 99.1 to an 8-K. The presentation provides updates on the company's business plan, and the filing includes no new financial results.
Presentation given September 14, 2026 at 2:00 p.m. ET; posted to the company website the same day
Kellyton Graphite Plant Phase 1 development capital of $245 million, with approximately $130 million spent as of June 30, 2026
$25 million EXIM direct loan approved for Kellyton, announced August 7, 2026
Cash on hand of $38.2 million as of June 30, 2026; Coosa permitting presentation projects production expected late 2028 / early 2029
Cryo-Cell International's Board has set October 27, 2026 as the date for its 2026 Annual Meeting of Stockholders, with September 21, 2026 as the record date for stockholders entitled to vote. The filing also notes that the bylaw deadlines for stockholder proposals and director nominations were July 27, 2026. This is a routine governance notice with no reported financial effect.
Annual Meeting of Stockholders scheduled for October 27, 2026
Record date for voting eligibility is September 21, 2026
Deadline for stockholder proposals and director nominations was July 27, 2026
Amended bylaws were previously filed as Exhibit 3.1 to a Form 8-K dated December 11, 2018
Firefly Neuroscience's board terminated Chief Financial Officer Paul Krzywicki on September 8, 2026, effective September 24, 2026, and stated the decision was not the result of any disagreement over the company's operations, policies or practices. The company also appointed Jessica Paz as Chief Accounting Officer, with an annual base salary of $215,000 and a stock option for 50,000 shares. The filing does not name a successor CFO.
Board terminated CFO Paul Krzywicki on September 8, 2026, effective September 24, 2026
Termination was stated to be unrelated to any disagreement on operations, policies or practices
Jessica Paz employed as Chief Accounting Officer effective September 8, 2026, at $215,000 annual base salary
Paz received a stock option for 50,000 shares, vesting over four years with 25% after the first anniversary
Plains All American Pipeline completed a public offering of $700 million of 6.750% Series A notes and $800 million of 7.000% Series B notes, both due December 15, 2056. The notes are unsecured and rank junior to PAA's existing and future senior debt, so holders would be paid after senior creditors, and no subsidiaries guarantee them. The filing shows the company is adding $1.5 billion in debt-like obligations, with interest rates that can reset in 2031 and 2036, subject to a floor at the initial rate.
Series A: $700 million, 6.750% coupon, due December 15, 2056; rate can adjust December 15, 2031 and every five years after.
Series B: $800 million, 7.000% coupon, due December 15, 2056; rate can adjust December 15, 2036 and every five years after.
Interest is payable June 15 and December 15, starting June 15, 2027; rates cannot reset below the initial rate.
Underwriting agreement dated September 9, 2026 with J.P. Morgan Securities LLC, Citigroup Global Markets Inc. and others; notes sold under a Form S-3 shelf filed September 6, 2024.
RGC Resources, Inc. filed a Form 8-K furnishing an updated investor presentation, Exhibit 99.1, for use in a September 14, 2026 meeting with analysts and investors. The filing contains no financial results, guidance or other new financial figures in its text, and the presentation is an image exhibit.
Company updated the slide presentation used in meetings with analysts, investors and the financial community.
The presentation was used at a September 14, 2026 meeting and posted on the company's website.
The filing is furnished under Regulation FD and is not deemed filed under Section 18 of the Exchange Act.
Orchid Island Capital (NYSE: ORC) declared a monthly cash dividend of $0.10 per share for September 2026, payable October 29, 2026 to holders of record on September 30, 2026. The filing also gives a preliminary snapshot of its RMBS portfolio as of August 31, 2026, showing about $11.15 billion in mortgage assets funded by about $10.70 billion in borrowings. The company says it has not set a minimum distribution level and cannot assure future payments.
Dividend: $0.10 per share, ex-dividend and record date September 30, 2026; payment date October 29, 2026
Next dividend announcement planned for October 14, 2026
Mortgage assets fair value of $11.15 billion as of August 31, 2026; 96.0% in whole pool assets
Shares outstanding fell to 197,407,315 as of September 14, 2026, from 198,407,315 on August 31, 2026
Genasys Inc. entered into a First Amendment to its loan agreement with Maran Partners Fund, LP, dated September 14, 2026, and reported it under Item 2.03 as a direct financial obligation. The filing does not state the amendment's amount, interest rate, maturity or changed terms in the text provided, so shareholders cannot yet judge its size or cost from this document.
Amendment is dated September 14, 2026, between Genasys Inc. and Maran Partners Fund, LP (Exhibit 10.1).
The filing is made under Items 1.01, 2.03 and 9.01; the Item 1.01 disclosure it incorporates is not included in the text provided.
No loan amount, interest rate or revised repayment terms are stated in the text provided.
Filing was signed by Chief Financial Officer Cassandra L. Hernandez-Monteon.
Crown Castle said CFO Sunit Patel will retire effective March 31, 2027, and that its board intends to appoint EVP and Chief Commercial Officer Kristoffer Hinson as CFO effective April 1, 2027. COO Cathy Piche will step down from her COO role on September 23, 2026, serve as a special advisor, and leave the company on February 22, 2027, with a search for her successor underway. The changes affect two senior executive roles, and no compensation terms for Hinson have been set yet.
Sunit Patel retires as EVP and CFO effective March 31, 2027, after the 2026 Form 10-K is filed.
Kristoffer Hinson, currently EVP and Chief Commercial Officer, is intended to become EVP and CFO effective April 1, 2027.
Cathy Piche leaves the COO role September 23, 2026, serves as special advisor, and departs February 22, 2027.
Hinson's compensation arrangements have not been determined; any required changes will be disclosed by amendment to this 8-K.
Health Catalyst appointed Tami Reller as a Class III director, effective October 1, 2026, expanding the board from six to seven members. She will also chair the Audit Committee and join the Compensation Committee. The company's press release also states that Simeon Kohl was named Chief Executive Officer and President, effective September 14, 2026.
Tami Reller appointed to the board effective October 1, 2026, filling a newly created seat
Board expands from six to seven directors, effective October 1, 2026
Reller replaces Justin Spencer as Audit Committee chair; Spencer remains on the committee
Press release states Simeon Kohl was named CEO and President effective September 14, 2026
iBio, Inc. filed an updated corporate presentation dated September 2026 as Exhibit 99.1 to a Form 8-K, for use in meetings with investors and analysts. The filing contains no new financial results, and the presentation reiterates pipeline timelines and a financial snapshot.
Presentation dated September 2026 furnished as Exhibit 99.1 under Items 7.01 and 8.01
Pipeline timelines include IBIO-610 IND-equivalent filing expected in 2H 2026 and IBIO-600 interim Phase 1 data anticipated in 1Q 2027
Financial snapshot shows $88.0 million in cash, cash equivalents and debt securities as of June 30, 2026, with runway extending into Q4 FY 2028
About 64.3 million shares outstanding as of August 30, 2026
American Tower completed a registered offering of $1.6 billion in senior unsecured notes across three maturities, with net proceeds of about $1,579.9 million. The company plans to use the proceeds to repay $600.0 million of 1.450% notes due 2026, repay borrowings under its $6.0 billion revolving credit facility, and for general corporate purposes. The new debt adds to the company's obligations, with interest rates from 5.300% to 5.750%.
Three tranches: $500.0 million 5.300% notes due September 15, 2031; $500.0 million 5.560% notes due September 15, 2033; $600.0 million 5.750% notes due September 15, 2036
Net proceeds of approximately $1,579.9 million after commissions and estimated expenses
Proceeds earmarked to repay $600.0 million of 1.450% notes due 2026 and revolver borrowings under the $6.0 billion facility
Interest is payable semi-annually beginning March 15, 2027; the notes are issued under a trustee, U.S. Bank Trust Company, National Association
Lululemon appointed Heidi O'Neill as chief executive officer and as a member of its board on September 8, 2026, ending the interim co-CEO roles of Meghan Frank and Andre Maestrini. The same day, the board adopted bylaw amendments covering stockholder nominations, meeting procedures and emergency operations, which shareholders may wish to review in the filed bylaws.
Heidi O'Neill began service as CEO and joined the board on September 8, 2026; the board increased from 11 to 12 members
Meghan Frank and Andre Maestrini ceased serving as interim co-CEOs as of September 8, 2026
Bylaws amended September 8, 2026, effective immediately, to update stockholder nomination and proposal procedures for universal proxy cards
A new Article XIII adds emergency bylaws for emergencies or disasters; full text filed as Exhibit 3.1
Ingles Markets added director Kevin Hefner to its board on September 8, 2026, and adopted amended and restated bylaws the same day that update shareholder meeting, nomination and removal procedures and add an exclusive forum provision. The company also moved its 2027 annual meeting to March 2, 2027, which changes the deadlines shareholders must meet to submit proposals or director nominations.
Kevin Hefner, 53, elected to the board on September 8, 2026, to fill the vacancy left by Brenda S. Tudor; he joins the Audit Committee and chairs the Compensation and Governance Committee
Amended and Restated Bylaws effective September 8, 2026, including an Executive Chairman provision and exclusive forum provisions for internal corporate claims
2027 Annual Meeting set for March 2, 2027; Rule 14a-8 proposals due by October 19, 2026, and bylaw nominations due between November 2 and December 2, 2026
Magnolia Oil & Gas completed its acquisition of WildFire Energy I LLC on September 10, 2026. The purchase price combined $2,570 million in cash, subject to final customary adjustments, 32,203,000 shares of Magnolia common stock, and the assumption of WildFire's $600.0 million 7.500% Senior Notes due 2029. The filing states that the share issuance was made under a Securities Act exemption and that resale registration rights were granted to the seller.
Acquisition completed September 10, 2026, with cash consideration of $2,570 million subject to final customary adjustments.
Equity consideration of 32,203,000 shares of common stock issued to seller WildFire Energy I LLC, with a 30-day lock-up on those shares.
Magnolia assumed the $600.0 million 7.500% Senior Notes due 2029, which mature October 15, 2029.
Magnolia Midstream LLC became a guarantor of Magnolia's 6.875% Senior Notes due 2032 and 6.625% Senior Notes due 2034.
First Citizens BancShares closed a public offering of 300,000 depositary shares, each a 1/100th interest in its new 7.500% Non-Cumulative Perpetual Preferred Stock, Series F, following a September 9, 2026 underwriting agreement. The new preferred ranks ahead of common stock and junior securities on dividends and liquidation, and carries no maturity date. Dividends are non-cumulative and payable only when declared by the board, so holders of common stock are not directly affected by the offering itself.
Offering of 300,000 depositary shares, each representing 1/100th of a $100,000 Series F preferred share, or $1,000 per depositary share; offering closed September 14, 2026
Dividend rate of 7.500% per annum until September 15, 2031, then resets to the five-year treasury rate plus 2.894%
Company may redeem on or after September 15, 2031, or within 90 days after a Regulatory Capital Treatment Event, subject to Federal Reserve approval
Holders elect two directors only if dividends are unpaid for periods totaling 18 months
Veracyte, Inc. completed its acquisition of Convergent Genomics on September 14, 2026, through a merger under an agreement signed September 10, 2026, adding the UroAmp urine tumor DNA platform for bladder cancer. The filing states the company did not update its previously provided 2026 adjusted EBITDA guidance, which already contemplated Convergent's operating expenses, and no financial results for Convergent were disclosed.
Upfront cash consideration of $150 million, subject to customary purchase price adjustments
Up to $30 million in additional cash tied to UroAmp publication and reimbursement milestones
Merger agreement dated September 10, 2026; closing completed September 14, 2026
Veracyte expects to commercialize its first UroAmp-based test in late 2028, subject to reimbursement timelines
Oxford Square Capital Corp. notified the trustee for its 5.50% Notes due 2028 that it will redeem $15 million of the $80.5 million outstanding principal on October 14, 2026. Holders will receive $25 per Note plus accrued and unpaid interest from July 31, 2026, which is a routine partial redemption that reduces the amount of Notes outstanding.
Redemption of $15,000,000 principal amount of the 5.50% Notes due 2028 (NasdaqGS: OXSQG)
Redemption date is October 14, 2026; $80.5 million of Notes were outstanding before the redemption
Redemption price is $25 per Note plus accrued and unpaid interest from July 31, 2026
INmune Bio's board increased its size to seven directors and appointed R. Duane Clark II and James Sapirstein as independent directors on September 8, 2026, with both also joining the Nominating and Corporate Governance Committee. The company says the appointments add rare-disease commercialization and business-development experience as it prepares its Ebstrocel candidate for potential commercialization.
Board set at seven directors; Clark and Sapirstein appointed on September 8, 2026, serving until the next annual election
Each director to receive an option to purchase 100,000 shares of common stock, vesting in 36 equal monthly installments
Each director to receive an annual cash retainer of $50,000, paid quarterly in arrears
Clark is General Manager, U.S. Rare Diseases at Sanofi; Sapirstein is CEO of Cocrystal Pharma, Inc. (Nasdaq: COCP)
On September 14, 2026, Scienture Holdings posted a revised investor presentation to its website and filed it as Exhibit 99.1 to a Form 8-K. The company said it intends to use the presentation in meetings with analysts and potential investors. The filing contains no financial results, guidance, or new financial figures, and the presentation speaks only as of the filing date.
The revised investor presentation was posted to the company's website on September 14, 2026 and is attached as Exhibit 99.1.
The company will use the presentation at various meetings with analysts, potential investors, and other interested parties.
The company disclaims any obligation to update the presentation and says it should be read with its SEC filings, including its Form 10-K for the year ending December 31, 2025.
Lesaka's compensation committee approved fiscal 2027 cash incentive awards for four executives, including CFO Dan Smith, whose base salary rose to ZAR 7,222,500 ($447,053) effective September 1, 2026. Awards range from 20% to 120% of base salary and depend on quantitative targets such as revenue, adjusted EBITDA and free cash flow conversion, plus qualitative goals, with the committee holding discretion to reduce payouts to zero.
CFO Dan Smith's annual base salary increased to ZAR 7,222,500 ($447,053), effective September 1, 2026
Mr. Smith's maximum fiscal 2027 award is 120% of base salary, or ZAR 8,667,000 ($536,464)
Mr. Heilbron and Mr. Kola each have a maximum award of $480,000, equal to 120% of a $400,000 base salary
The committee may reduce or eliminate any award, including reducing payouts to zero, regardless of whether targets are achieved
Inseego director Stephen Bye notified the company on September 14, 2026 that he will resign from its Board of Directors effective September 30, 2026. The filing says he is leaving to become CEO of WW International and that the resignation was not due to any disagreement with Inseego on its operations, policies or practices.
Resignation notice given September 14, 2026; effective September 30, 2026
Stated reason: forthcoming appointment as Chief Executive Officer of WW International, Inc. (Nasdaq: WW)
Filing states no disagreement with the company on operations, policies or practices
CPI Card Group's major stockholders, Tricor Pacific funds, sold shares in a public offering that closed on September 14, 2026, including a fully exercised underwriter option. The company sold no shares and received no proceeds, so the deal changes its share count and ownership mix rather than its capital.
Selling stockholders offered 2,337,323 common shares under an underwriting agreement dated September 10, 2026, with B. Riley Securities as representative.
Underwriters exercised in full an option to buy 350,598 additional shares on September 11, 2026.
The offering closed on September 14, 2026; the company did not sell any securities and receives no proceeds.
The offering was made under a Form S-3 shelf registration declared effective September 22, 2021.
Elicio Therapeutics has set November 12, 2026 as the date of its 2026 annual meeting of stockholders. Because the meeting date moves by more than 30 days from the anniversary of its last annual meeting, the company set September 24, 2026 as the deadline for stockholder proposals and director nominations.
Annual meeting date set for November 12, 2026; exact time, location and voting matters to be detailed in the proxy statement
Deadline for Rule 14a-8 stockholder proposals and bylaw notices of director nominations: September 24, 2026
Universal proxy notices under Rule 14a-19 also due by September 24, 2026
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Briefs marked “Written later” were written in November 2026 for filings that were by then more than three weeks old, so months before mid-October 2026 hold a selection: every material 8-K of the past year for the 100 largest companies we cover and the last 15 important 8-Ks of every other one. Briefs the number check holds back are not shown or counted. Also: the last 45 days, briefs by company, A–Z and the live SEC filings wire.